{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-167467","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2024-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.102227+00:00","generated_at":"2026-06-01T02:14:49.776969+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Werewolf Therapeutics' WTX-330 Phase 1 shows unconfirmed partial response in melanoma; improved tolerability","bullets":["WTX-330 achieved 23-fold higher systemic IL-12 prodrug concentration vs rhIL-12 at 0.024 mg/kg; free IL-12 <1.6% of prodrug (cutoff June 12, 2024).","Unconfirmed partial response in metastatic melanoma patient who had progressed on adjuvant pembrolizumab; confirmatory scan pending.","Two MSS CRC patients achieved stable disease (one for 24 weeks); evidence of CD8+ T and NK cell activation in tumor biopsies.","No Grade 4/5 treatment-related AEs; mild-moderate toxicities (fever, chills, cytopenias) primarily first dose; MTD not established.","Expansion arms open at 0.024 mg/kg for ICI-resistant or ICI-naive patients; additional data expected Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-167467","json":"https://secwatch.observer/filing/0001193125-24-167467.json","markdown":"https://secwatch.observer/filing/0001193125-24-167467.md","text":"https://secwatch.observer/filing/0001193125-24-167467.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524167467/0001193125-24-167467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312524167467/d857404d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:14:49.776969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}